Why the study?
Despite guideline-directed medical therapy, ACS patients retain a higher risk for recurrence due to ongoing inflammation, and prior anti-inflammatory strategies have not shown benefit.
Does colchicine improve outcomes in patients with acute coronary syndrome?
Does colchicine improve outcomes in patients with acute coronary syndrome?
This review explores the potential of colchicine as an anti-inflammatory therapy to reduce recurrence risk in acute coronary syndrome.
Answers are grounded in this paper and cite their sources.
Colchicine addition to GDMT may reduce residual inflammatory risk in ACS; reinforces anti-inflammatory strategies in secondary prevention.
Inflammation is identified as a keystone of atherosclerosis. This review of the literature explores the unique anti-inflammatory effects of colchicine and summarizes the mechanisms of inflammation in acute coronary syndrome. It outlines other therapeutic strategies employed until now to target coronary inflammation and analyzes the role of colchicine in improving the outcomes of acute coronary syndrome. Despite the existence of guideline-directed medical therapy, there still remains a higher risk for recurrence due to continuous inflammation at remaining vascular sites. Several anti-inflammatory strategies have been employed, but they have not been shown to be beneficial. However, colchicine is becoming increasingly popular in tackling this problem. For this review, databases were searched for trials on the role of colchicine as an anti-inflammatory therapy in acute coronary syndrome.
No takes yet. Share an insight, caveat, or question.
Malik et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: